<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03275493</url>
  </required_header>
  <id_info>
    <org_study_id>UnicarTherapy201701</org_study_id>
    <nct_id>NCT03275493</nct_id>
  </id_info>
  <brief_title>Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Humanized Chimeric Antigen Receptor T Cells Against CD19 With Cytokine Release Syndrome (CRS) Suppression Technology for Refractory/Relapsed CD19+ Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the
      efficacy and safety of T cells expressing humanized CD19 chimeric antigen receptors treatment
      for relapsed/refractory CD19+ acute lymphoblastic leukemia patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Relapsed/refractory CD19 + acute lymphoblastic leukemia patients were randomly enrolled in
      this study to compare the efficacy and safety between two cohorts: 1. Humanized CD19 CAR-T
      cells； 2. Humanized CD19 CAR-T cells with CRS suppression technology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">September 18, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 18, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of severe CRS</measure>
    <time_frame>30 days after infusion of humanized CD19 CAR-T cells</time_frame>
    <description>The safety of the humanized CD19 CAR-T cells treatment will be evaluated and the maximum tolerated dose will be determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response of humanized CD19 CAR-T cells treatment who achieve morphology complete remission(CR) and MRD negativity.</measure>
    <time_frame>30 days after infusion of humanized CD19 CAR-T cells</time_frame>
    <description>The efficacy of the humanized CD19 CAR-T cells infusion will be estimated based on the number of participants who have morphology complete remission(CR) and MRD negativity following the humanized CD19 CAR- T cells infusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>CD19 Positive</condition>
  <condition>Relapse</condition>
  <condition>Refractory</condition>
  <arm_group>
    <arm_group_label>Experimental: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells for CD19+ acute lymphoblastic leukemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will determine the safety and efficacy of humanized CD19 CAR-T cells with CRS suppression technology for CD19+ acute lymphoblastic leukemia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humanized CD19 CAR-T cells</intervention_name>
    <description>Express a Second Generation 4-1BB:humanized CD19 CAR-T cells</description>
    <arm_group_label>Experimental: Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Humanized CD19 CAR-T cells with CRS suppression technology</intervention_name>
    <description>Express a Second Generation 4-1BB:humanized CD19 CAR-T cells with CRS suppression technology</description>
    <arm_group_label>Experimental: Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 6 to 65

          2. Voluntary informed consent is given

          3. Expected survival ≥12 weeks

          4. Relapsed or refractory CD19+ acute leukemia, ineligible for allo-HSCT,or relapse after
             auto-HSCT

          5. Organ function: (1)Left ventricular ejection fractions≥ 0.6 by echocardiography (2)ALT
             ≤3 times of ULN, or bilirubin &lt;2.0 mg/dl (3)Creatinine &lt; 2 mg/dl and less than 2.5 ×
             normal for age (4)Prothrombin time and activated partial thromboplastin time &lt; 2 times
             of ULN (5)Arterial oxygen saturation&gt; 92%

          6. Karnofsky score ≥ 60 ;

          7. No history of combined chemotherapy in the recent 1 month and no immunotherapy in the
             recent 3 months;

        Exclusion Criteria:

          1. Uncontrolled active infections

          2. Active hepatitis B or hepatitis C infection

          3. HIV infection

          4. History of myocardio infarction in the past 6 months, or history of severe arrhythmia

          5. Congenital immunodeficiency

          6. Pregnant or lactating women

          7. History or presence of clinically relevant CNS pathology such as epilepsy, generalized
             seizure disorder, paresis, aphasia, stroke, severe brain injuries, dementia,
             Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis

          8. Previous treatment with any gene therapy products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaowen Tang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaowen Tang, PhD</last_name>
    <phone>8651267781525</phone>
    <email>tangxiaowen@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Yu, PhD</last_name>
    <phone>8613818629089</phone>
    <email>ylyh188@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of soochow university</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengli Xue, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD19+ ,CAR-T, CRS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

